Indication
HIV-1 Infection
33 clinical trials
47 products
Product
ISLClinical trial
A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVStatus: Active (not recruiting), Estimated PCD: 2023-12-19
Product
LENProduct
B/F/TAFClinical trial
A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine/Islatravir in Pediatric Participants With HIV-1 Infection Who Are Virologically Suppressed or Treatment-Naïve, Are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kgStatus: Completed, Estimated PCD: 2021-12-21
Product
DOR/ISLProduct
IslatravirClinical trial
A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-DailyStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Product
UlonivirineProduct
BIC/FTC/TAFClinical trial
A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical StudyStatus: Active (not recruiting), Estimated PCD: 2027-10-15
Product
MK-8591AProduct
PlaceboClinical trial
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Adolescents and ChildrenStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 InfectionStatus: Completed, Estimated PCD: 2023-04-18
Clinical trial
A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)Status: Completed, Estimated PCD: 2018-02-22
Product
DoravirineProduct
UB-421Product
HAARTClinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial With UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 InfectionStatus: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISLStatus: Completed, Estimated PCD: 2022-11-21
Clinical trial
A Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected AdultsStatus: Withdrawn, Estimated PCD: 2025-12-31
Product
DORClinical trial
A Clinical Trial to Study the Effect of a Single Dose of Islatravir (MK-8591) on the Pharmacokinetics of MethadoneStatus: Completed, Estimated PCD: 2021-07-09
Product
LenacapavirProduct
TeropavimabProduct
ZinlirvimabProduct
chidamideClinical trial
A Phase II Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs Among ART Stabilized HIV-1 Patients Who Undergo ART InterruptionStatus: Completed, Estimated PCD: 2023-02-01
Clinical trial
A Phase I, Open-Label, Multi-Dose Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive PatientsStatus: Completed, Estimated PCD: 2022-05-25
Clinical trial
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-8507 in HIV-1 Infected PatientsStatus: Completed, Estimated PCD: 2015-07-16
Product
LamivudineClinical trial
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve AdultsStatus: Completed, Estimated PCD: 2021-03-08
Product
Doravirine/IslatravirClinical trial
A Phase 1, Open-label, Multicohort Study to Evaluate the Impact of Inhibitors and Inducers of Cytochrome P450 Enzyme (CYP)3A, P-glycoprotein (P-gp), and Breast Cancer Resistant Protein (BCRP) on the Pharmacokinetics (PK) of Vesatolimod (VES) in Virologically Suppressed Adults With HIV-1 on Antiretroviral Therapy (ART)Status: Terminated, Estimated PCD: 2023-10-13
Product
VesatolimodProduct
CobicistatProduct
VoriconazoleProduct
RifabutinClinical trial
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)Status: Active (not recruiting), Estimated PCD: 2024-11-13
Clinical trial
A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve ParticipantsStatus: Active (not recruiting), Estimated PCD: 2022-11-17
Clinical trial
Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer ConstructStatus: Active (not recruiting), Estimated PCD: 2031-10-01
Product
Blood testsClinical trial
A Phase 3, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Antiretroviral TherapyStatus: Active (not recruiting), Estimated PCD: 2024-10-30
Product
ARTClinical trial
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low- Risk for HIV-1 InfectionStatus: Completed, Estimated PCD: 2022-03-18
Clinical trial
Implementation of Out-of-HOspital Administration of the Long-Acting Combination Cabotegravir+Rilpivirine as an Optional Therapy in HIV-Infected Patients From Spain: Acceptability, Appropriateness, Feasibility and Satisfaction: The HOLA StudyStatus: Recruiting, Estimated PCD: 2025-03-01
Product
Vocabria (cabotegravir)Product
Vocabria + RekambysClinical trial
Efficacy of Atazanavir / Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression. Randomized, Open Label Non Inferiority Trial. A Phase 3 Study.Status: Completed, Estimated PCD: 2013-07-01
Product
Atazanavir + RitonavirClinical trial
A Single Arm Open Label Phase 2 Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 InfectionStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve ParticipantsStatus: Recruiting, Estimated PCD: 2025-10-19
Clinical trial
Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors. A 24-week Open-label, Proof-of-concept Pilot Clinical Trial.Status: Completed, Estimated PCD: 2014-05-01
Product
IsentressClinical trial
A Pilot Phase II Study of a Nucleoside Sparing Regimen of Dolutegravir + Atazanavir/r in HIV-1 Infected Patients With Detectable Viremia (DOLATAV Study)Status: Completed, Estimated PCD: 2016-06-01
Clinical trial
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 InfectionStatus: Recruiting, Estimated PCD: 2026-06-01
Product
DasatinibClinical trial
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)Status: Completed, Estimated PCD: 2023-08-21
Product
PitavastatinProduct
PlacebosClinical trial
Pilot Study: Single Arm, Multi-site, Open-label Study to Assess the Effectiveness of Peg-IFN-a2b in Decreasing the Levels of Cell-associated Integrated Viral DNA in HIV Chronic InfectionStatus: Completed, Estimated PCD: 2015-03-25
Clinical trial
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune ResponsesStatus: Active (not recruiting), Estimated PCD: 2020-12-02
Clinical trial
IGHID 11627 - A Phase I Study to Evaluate the Effects of Vorinostat and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on Persistent HIV-1 Infection in HIV-Infected Individuals Started on Antiretroviral Therapy (The XTRA Study)Status: Completed, Estimated PCD: 2022-06-07
Product
VorinostatProduct
HXTCClinical trial
WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 WeeksStatus: Completed, Estimated PCD: 2022-04-30
Product
DolutegravirProduct
Tenofovir AlafenamideProduct
TruvadaProduct
Atripla